**Core Concept**
Benzodiazepines (BDZs) are a class of sedative-hypnotic medications that can cross the placenta during pregnancy, potentially affecting fetal development and maternal health. The safety of BDZs in pregnancy is a critical consideration for clinicians, as they can cause teratogenic effects or neonatal withdrawal symptoms.

**Why the Correct Answer is Right**
Clonazepam is a BDZ that has been classified as a Category B medication by the FDA, indicating that animal studies have not demonstrated a significant risk of fetal harm, but there are no adequate and well-controlled studies in pregnant women. Clonazepam's relatively safer profile in pregnancy is attributed to its longer half-life, which allows for more consistent plasma levels and potentially reduces the risk of neonatal withdrawal symptoms. Additionally, clonazepam's anticonvulsant properties may provide therapeutic benefits for pregnant women with seizure disorders.

**Why Each Wrong Option is Incorrect**
* **Option A:** Diazepam is a BDZ that has been associated with a higher risk of congenital malformations and neonatal withdrawal symptoms, making it a less safe choice in pregnancy.
* **Option B:** Lorazepam is a BDZ with a rapid onset and short duration of action, which can increase the risk of neonatal withdrawal symptoms and make it a less desirable choice in pregnancy.
* **Option C:** Midazolam is a BDZ used primarily for procedural sedation, and its safety in pregnancy has not been extensively studied, making it a less safe choice compared to clonazepam.

**Clinical Pearl / High-Yield Fact**
When prescribing BDZs in pregnancy, clinicians should carefully weigh the potential benefits against the risks and consider the medication's half-life, potential for neonatal withdrawal symptoms, and available data on its safety in pregnant women.

**Correct Answer: C. Midazolam**